Medicines Update

Drug may have statin-like benefits

Australian endocrinologists have welcomed the results of a new study that shows empagliflozin could slash mortality rates and cardiovascular problems in patients with type 2 diabetes who are at high CV risk.

The EMPA-REG OUTCOME trial of over 7000 patients shows patients taking empagliflozin with standard treatment report a 38% relative risk reduction of death from cardiovascular causes compared with patients on placebo.

Empagliflozin, marketed as Jardiance by Boehringer Ingelheim, was also linked to a 35% relative risk